| Affimed is a clinical-stage biopharmaceutical company focused on discovering and developing targeted cancer immunotherapies. Co.'s lead candidate, AFM13, is an innate cell engager designed for the treatment of certain CD30-positive (CD30+) B- and T cell malignancies. Co.'s second clinical stage candidate, AFM11, is a T cell engager designed for the treatment of certain CD19+ B cell malignancies, including non-Hodgkin Lymphoma and Acute Lymphocytic Leukemia. Co.'s third candidate, AFM24, is an innate cell-engaging bispecific antibody targeting EGFR. Co. has also developed AFM26, an innate cell-engaging bispecific antibody targeting B cell maturation antigen to treat multiple myeloma. We show 7 historical shares outstanding datapoints in our AFMD shares outstanding history coverage, used to compute AFMD market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing AFMD market cap history over the course of time is important for investors
interested in comparing AFMD's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of AFMD versus a peer is one thing; comparing
AFMD market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like AFMD can fluctuate over the course of history.
With this page we aim to empower investors researching AFMD by allowing them to research the AFMD market cap history.